FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3203057068> ?p ?o ?g. }

• W3203057068 endingPage "1387" @default.
• W3203057068 startingPage "1377" @default.
• W3203057068 abstract "BACKGROUND: Ovarian cancer (OC) is the fifth leading cause of cancer death in women and has the highest mortality rate of gynecological cancers. Niraparib was recently approved by the FDA for the maintenance treatment of adult patients with advanced epithelial OC in complete or partial response to first-line platinum-based chemotherapy (PBC) regardless of biomarker status. OBJECTIVE: To estimate the direct economic impact on US payers of adding niraparib as a first-line maintenance therapy for patients with advanced OC. METHODS: The model considered 2 scenarios: a current scenario in which niraparib does not have regulatory approval for first-line maintenance therapy and a future scenario in which niraparib has regulatory approval for first-line maintenance therapy. The budget impact was calculated as the difference in cost between the 2 scenarios. The budget impact model (BIM) considered 2 different US health care payer perspectives: a commercial health plan and a Medicare plan. Both payer perspectives were assumed to have a hypothetical 1 million affiliates that were covered. Epidemiological data was used to estimate the eligible incident population of patients with OC. Active surveillance, bevacizumab (as a monotherapy), and olaparib (as a monotherapy restricted to patients with the breast cancer gene [BRCA] mutation) were included in the model as alternative maintenance treatment options (maintenance treatment options required 1% market share for inclusion). Cost categories considered in the BIM included diagnostic testing, treatment acquisition and administration, treatment-emergent adverse events, and subsequent therapy. Results were presented as an incremental budget impact to payers over 3 years. RESULTS: For a commercial health plan of 1 million affiliates, the estimated impact of adding niraparib as a first-line maintenance treatment option for advanced epithelial OC was calculated as $87,906, $93,106, and $87,037 for years 1, 2, and 3, respectively. The average budget impact per member per month was $0.007. For a Medicare health plan of 1 million affiliates, the estimated impact was calculated as $206,785, $219,017, and $204,739 for years 1, 2, and 3, respectively. The average budget impact per member per month was $0.018. One-way sensitivity analyses suggested that budget impact was most sensitive to the treatment duration and market share of niraparib, the non-treatment-specific data on overall survival rates, and the treatment duration of bevacizumab. Treatment of drug-specific adverse events had little impact on the budget model. CONCLUSIONS: The model estimated a minimal budget impact to both a commercial or Medicare health plan following the introduction of niraparib as a first-line maintenance therapy for patients with advanced epithelial OC who are in complete or partial response to first-line PBC regardless of biomarker status. DISCLOSURES: This study was financially supported by GlaxoSmithKline. Liu, Hawkes, Maiese, and Hurteau are employees of GlaxoSmithKline. Travers was employed by GlaxoSmithKline at the time of this study. Spalding and Walder are employees of FIECON Ltd., which was contracted by GlaxoSmithKline to develop the budget impact model used in this study." @default.
• W3203057068 created "2021-10-11" @default.
• W3203057068 creator A5015424048 @default.
• W3203057068 creator A5022179689 @default.
• W3203057068 creator A5027207573 @default.
• W3203057068 creator A5033266357 @default.
• W3203057068 creator A5070660065 @default.
• W3203057068 creator A5084169741 @default.
• W3203057068 creator A5091357745 @default.
• W3203057068 date "2021-10-01" @default.
• W3203057068 modified "2023-09-23" @default.
• W3203057068 title "Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective" @default.
• W3203057068 cites W2046912846 @default.
• W3203057068 cites W2119679249 @default.
• W3203057068 cites W2131553265 @default.
• W3203057068 cites W2528228811 @default.
• W3203057068 cites W2572458419 @default.
• W3203057068 cites W2575745105 @default.
• W3203057068 cites W2771491442 @default.
• W3203057068 cites W2810447459 @default.
• W3203057068 cites W2897430921 @default.
• W3203057068 cites W2934033909 @default.
• W3203057068 cites W2975141952 @default.
• W3203057068 cites W2994977341 @default.
• W3203057068 cites W3002796847 @default.
• W3203057068 doi "https://doi.org/10.18553/jmcp.2021.27.10.1377" @default.
• W3203057068 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34595950" @default.
• W3203057068 hasPublicationYear "2021" @default.
• W3203057068 type Work @default.
• W3203057068 sameAs 3203057068 @default.
• W3203057068 citedByCount "0" @default.
• W3203057068 crossrefType "journal-article" @default.
• W3203057068 hasAuthorship W3203057068A5015424048 @default.
• W3203057068 hasAuthorship W3203057068A5022179689 @default.
• W3203057068 hasAuthorship W3203057068A5027207573 @default.
• W3203057068 hasAuthorship W3203057068A5033266357 @default.
• W3203057068 hasAuthorship W3203057068A5070660065 @default.
• W3203057068 hasAuthorship W3203057068A5084169741 @default.
• W3203057068 hasAuthorship W3203057068A5091357745 @default.
• W3203057068 hasBestOaLocation W32030570681 @default.
• W3203057068 hasConcept C104317684 @default.
• W3203057068 hasConcept C121608353 @default.
• W3203057068 hasConcept C126322002 @default.
• W3203057068 hasConcept C143998085 @default.
• W3203057068 hasConcept C177713679 @default.
• W3203057068 hasConcept C182979987 @default.
• W3203057068 hasConcept C185592680 @default.
• W3203057068 hasConcept C2776694085 @default.
• W3203057068 hasConcept C2777802072 @default.
• W3203057068 hasConcept C2778283404 @default.
• W3203057068 hasConcept C2779962180 @default.
• W3203057068 hasConcept C2780194787 @default.
• W3203057068 hasConcept C2780427987 @default.
• W3203057068 hasConcept C2908647359 @default.
• W3203057068 hasConcept C55493867 @default.
• W3203057068 hasConcept C71924100 @default.
• W3203057068 hasConcept C82381507 @default.
• W3203057068 hasConcept C99454951 @default.
• W3203057068 hasConceptScore W3203057068C104317684 @default.
• W3203057068 hasConceptScore W3203057068C121608353 @default.
• W3203057068 hasConceptScore W3203057068C126322002 @default.
• W3203057068 hasConceptScore W3203057068C143998085 @default.
• W3203057068 hasConceptScore W3203057068C177713679 @default.
• W3203057068 hasConceptScore W3203057068C182979987 @default.
• W3203057068 hasConceptScore W3203057068C185592680 @default.
• W3203057068 hasConceptScore W3203057068C2776694085 @default.
• W3203057068 hasConceptScore W3203057068C2777802072 @default.
• W3203057068 hasConceptScore W3203057068C2778283404 @default.
• W3203057068 hasConceptScore W3203057068C2779962180 @default.
• W3203057068 hasConceptScore W3203057068C2780194787 @default.
• W3203057068 hasConceptScore W3203057068C2780427987 @default.
• W3203057068 hasConceptScore W3203057068C2908647359 @default.
• W3203057068 hasConceptScore W3203057068C55493867 @default.
• W3203057068 hasConceptScore W3203057068C71924100 @default.
• W3203057068 hasConceptScore W3203057068C82381507 @default.
• W3203057068 hasConceptScore W3203057068C99454951 @default.
• W3203057068 hasIssue "10" @default.
• W3203057068 hasLocation W32030570681 @default.
• W3203057068 hasLocation W32030570682 @default.
• W3203057068 hasOpenAccess W3203057068 @default.
• W3203057068 hasPrimaryLocation W32030570681 @default.
• W3203057068 hasRelatedWork W2950446512 @default.
• W3203057068 hasRelatedWork W2994977341 @default.
• W3203057068 hasRelatedWork W3030399171 @default.
• W3203057068 hasRelatedWork W3047344552 @default.
• W3203057068 hasRelatedWork W3090114554 @default.
• W3203057068 hasRelatedWork W3113307403 @default.
• W3203057068 hasRelatedWork W3191066603 @default.
• W3203057068 hasRelatedWork W4241478731 @default.
• W3203057068 hasRelatedWork W4379333725 @default.
• W3203057068 hasRelatedWork W4382199459 @default.
• W3203057068 hasVolume "27" @default.
• W3203057068 isParatext "false" @default.
• W3203057068 isRetracted "false" @default.
• W3203057068 magId "3203057068" @default.
• W3203057068 workType "article" @default.